Latest Oncology News

BXCL701 Plus Pembrolizumab is Safe and Generates Early Antitumor Activity in Advanced PDAC

August 4th 2025

Ashley Chan

Benjamin A. Weinberg, MD, FACP, discusses the potential role of BXCL701 plus pembrolizumab in advanced pancreatic ductal adenocarcinoma.

NIAGARA Data Raise Questions About the Role of MVAC in Resectable MIBC

August 4th 2025

Ashling Wahner

Waddah Arafat, MD, discusses the treatment paradigm for MIBC and questions regarding the benefit seen with neoadjuvant chemoimmunotherapy in this setting.

CaRe Prostate Study of INKmune in Metastatic CRPC Hits Primary, Secondary End Points

August 4th 2025

Kyle Doherty

The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.

Northwell Cancer Institute Names Global Oncology Researcher Geraldine O’Sullivan Coyne, MD, PhD, to lead START Unit’s Early-Stage Clinical Trials

August 4th 2025

Northwell Health

Northwell Cancer Institute appointed Geraldine O’Sullivan Coyne, MD, to The START Center for Cancer Research to bring trials to the community setting.

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia

August 4th 2025

Ashley Chan

The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

Latest Oncology Videos

Dr McKay on the Role of Casdatifan Plus Cabozantinib in Clear Cell RCC

Final Thoughts and Future Perspectives in SCLC

Dr George on the Clinical Relevance of Targetable Mutations in GIST

Introducing Treatment-Free Remission (TFR) to Patients Early in Their Treatment Course for CP-CML

Addressing Further Unmet Needs in PNH

Dr Maese on Asparaginase-Based Regimens in Adult/Young Adult ALL

Coordinated Care in Breast Oncology: Encouraging Participation in Clinical Trials

Voices in Lymphoma: Women Shaping the Future of Care

Molecular Testing in Lung Cancer: Personalized Diagnostics Are Transforming Care

Dr Shah on Outcomes With Checkpoint Inhibition in Patients With Cancer and Pre-Existing Neurologic Autoimmune Disorders

Emerging ADCs in SCLC: Spotlight on B7-H3 and MHB088C

Treating Through Toxicities in CLL—Decisions Around BTKi Continuity

Managing Adverse Effects in CLL—BTKi Toxicities in Focus

Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC

Dr Khan on the Role of Acalabrutinib in the Current CLL Treatment Paradigm

Coordinated Care in Breast Oncology: Systemic Therapy Trials and Personalized Approaches

Dr Pelz on the Role of Minimally Invasive Surgical Techniques in Lung Cancer

Talquetamab: Efficacy, AE Management, and Outpatient Strategies and Insights From ASCO 2025

The Clinical Impact of Treatment Intolerance and Nonadherence in CP-CML

Key Takeaways and Future Questions in Perioperative GC/GEJC

Insights Into CAR T Therapy in Earlier vs Later Lines

Coordinated Care in Breast Oncology: Clinical Trials and De-escalation of Treatment

Dr Braun on Fundamental Immune Defects in Chromophobe RCC

All Oncology News

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen

August 4th 2025

Ashling Wahner

Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

Retrospective Data Show Feasibility of Checkpoint Inhibition in Patients With Cancer and Neurologic Autoimmune Disorders

August 4th 2025

Chris Ryan

A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.

Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC

August 4th 2025

Kyle Doherty

Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management

August 4th 2025

Courtney Flaherty

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Five Under 5: Top Oncology Videos for the Week of 7/27

August 3rd 2025

OncLive Staff

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

First‑in‑Class mRNA‑2416 Shows Tolerability, Biologic Activity in Ovarian Cancer and Other Advanced Solid Tumors

August 3rd 2025

Jax DiEugenio

mRNA‑2416, alone or with durvalumab, was well tolerated and biologically active in advanced solid tumors and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

OncLive Staff

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis

August 2nd 2025

Caroline Seymour

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

TAR‑200 Could Alter Nonsurgical Management of BCG‑Unresponsive NMIBC

August 1st 2025

Jax DiEugenio

Joseph Jacob, MD, MCR, discusses how TAR‑200 could represent a new treatment avenue in BCG‑unresponsive, high-risk NMIBC.

Final Phase 3 Data Underscore Role of Pembrolizumab/Chemoradiotherapy in High Risk, Locally Advanced Cervical Cancer

August 1st 2025

Jax DiEugenio

Linda Duska, MD, MPH, discusses final results of KEYNOTE A18 for pembrolizumab plus chemoradiotherapy in high risk, locally advanced cervical cancer.

Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer

August 1st 2025

Ashley Chan

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Mayo Clinic Treats First Person in the US With a Novel Radiopharmaceutical Therapy for Breast Cancer

August 1st 2025

Mayo Clinic

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma

August 1st 2025

Ashley Chan

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

VT3989 Receives FDA Orphan Drug Designation for Mesothelioma

August 1st 2025

Courtney Flaherty

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

OncLive Staff

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

See All News